Filtered By:
Condition: Liver Disease
Vaccination: Hepatitis Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 197 results found since Jan 2013.
Inhibitors Targeting Hepatitis C Virus (HCV) Entry
Mini Rev Med Chem. 2023;23(11):1193-1221. doi: 10.2174/1389557522666220428115152.ABSTRACTInfections caused by the Hepatitis C virus (HCV) affect around 70 million people worldwide, leading to serious liver problems, such as fibrosis, steatosis, and cirrhosis, in addition to progressing to hepatocellular carcinoma and becoming globally the main cause of liver disease. Despite great therapeutic advances in obtaining pan-genotypic direct-acting antivirals (DAAs), around 5-10% of affected individuals are unable to eliminate the virus by their own immune system's activity. Still, there are no licensed vaccines so far. In this c...
Source: Mini Reviews in Medicinal Chemistry - July 10, 2023 Category: Chemistry Authors: Paulo Fernando da Silva Santos-J únior Jo ão Xavier de Araújo-Júnior Edeildo Ferreira da Silva-J únior Source Type: research
Gastrointestinal tract and viral pathogens
World J Virol. 2023 Jun 25;12(3):136-150. doi: 10.5501/wjv.v12.i3.136.ABSTRACTViral gastroenteritis is the most common viral illness that affects the gastrointestinal (GI) tract, causing inflammation and irritation of the lining of the stomach and intestines. Common signs and symptoms associated with this condition include abdominal pain, diarrhea, and dehydration. The infections commonly involved in viral gastroenteritis are rotavirus, norovirus, and adenovirus, which spread through the fecal-oral and contact routes and cause non-bloody diarrhea. These infections can affect both immunocompetent and immunocompromised indiv...
Source: Herpes - July 3, 2023 Category: Infectious Diseases Authors: Gowthami Sai Kogilathota Jagirdhar Yashwitha Sai Pulakurthi Himaja Dutt Chigurupati Salim Surani Source Type: research
Chronic Hepatitis B Infection: Current and Emerging Therapeutic Strategies
This article summarizes the current landscape of HBV treatments, and drugs in clinical trials and highlights the most recent anti-HBV small molecules designed to directly target HBV or to improve immune response during chronic infection.PMID:37069708 | DOI:10.2174/1568026623666230413094331
Source: Current Topics in Medicinal Chemistry - April 18, 2023 Category: Chemistry Authors: Ankita Singh Jitendra Kumar Vijay Kumar Source Type: research
Autoimmune liver diseases and SARS-CoV-2
World J Gastroenterol. 2023 Mar 28;29(12):1838-1851. doi: 10.3748/wjg.v29.i12.1838.ABSTRACTSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19), can trigger autoimmunity in genetically predisposed individuals through hyperstimulation of immune response and molecular mimicry. Here we summarise the current knowledge about auto-immune liver diseases (AILDs) and SARS-CoV-2, focusing on: (1) The risk of SARS-CoV-2 infection and the course of COVID-19 in patients affected by AILDs; (2) the role of SARS-CoV-2 in inducing liver damage and triggering AILDs; and (3) the ability of...
Source: World Journal of Gastroenterology : WJG - April 10, 2023 Category: Gastroenterology Authors: Costantino Sgamato Alba Rocco Debora Compare Stefano Minieri Stefano Andrea Marchitto Simone Maurea Gerardo Nardone Source Type: research
